Deguelin

Deguelin
File:Deguelin.png
IUPAC name (7aS,13aS)-13,13a-Dihydro-9,10-dimethoxy-3,3-dimethyl-3H-bis[1]benzopyrano [3,4-b:6’,5’-3]pyran-7(7aH)-one
Other names Deguelin; 3H-Bis(1)benzopyrano (3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3- dimethyl-, (7aS,13aS)-; 3H-Bis(1) benzopyrano(3,4-b:6',5'-e)pyran- 7(7aH)-one, 13,13a-dihydro- 9, 10-dimethoxy-3,3-dimethyl-, (7aS-cis)-
style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers
CAS number	522-17-8
SMILES
InChI
style="background: #F8EABA; text-align: center;" colspan="2" | Properties
Molecular formula	C23H22O6
Molar mass	394.42 g/mol
Melting point	171 °C, 444 K, 340 °F
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Deguelin is a derivative of rotenone. Both are compounds classified as rotenoids of the flavonoid family and are naturally occurring insecticides. They can be produced by extraction from several plant species belonging to three genera of the Fabaceae or Legume family, Lonchocarpus, Derris, or Tephrosia.

Cubé resin, the root extract from Cubé (Lonchocarpus utilis) and from Barbasco (Lonchocarpus urucu), is used as a commercial insecticide and piscicide (fish poison). The major active ingredients are rotenone and deguelin. Although "organic" (produced by nature) cubé resin is no longer considered environmentally safe.

Pharmacokinetics

• Mean residence time (MRT) = 6.98 h
• Terminal half-life (t1/2(gamma)) = 9.26 h
• Area under the curve (AUC) = 57.3 ng h/ml
• Total clearance (Cl) = 4.37 l/h per kg
• Apparent volume of distribution (V) = 3.421 l/kg
• Volume of distribution at steady-state (Vss) = 30.46 l/kg
• Tissue distributions after i.v. (intravenous) administration: heart > fat > mammary gland > colon > liver > kidney > brain > lung.
• Tissue distributions after i.g. (intragastric) administration: perirenal fat > heart > mammary gland > colon > kidney > liver > lung > brain > skin.
• Elimination: Within 5 days of i.g. administration, about 58.1% of the [3H]deguelin was eliminated via the feces and 14.4% via the urine. Approximately 1.7% of unchanged deguelin was found in the feces, and 0.4% in the urine.

Deguelin and Anti-cancer activity

Deguelin displays anti-cancer activity by inhibiting the growth of pre-cancerous and cancerous cells - particularly for lung cancer. So far the compound has shown no toxic effects on normal cells. However, high doses of deguelin are suspected of having negative effects on the heart, lungs and nerves. The molecular mechanisms include the induction of apoptosis, mediatated through AKT/PKB signaling pathways in malignant and premaligant human bronchial epithelia (HBE) cells, with only minimal effects on normal HBE cells. Deguelin inhibits AKT by both Phosphoinositol-3-phosphate kinase (PI3K)-dependent and PI3K-independent pathways.

Deguelin and Parkinson's disease

Research has shown a correlation between intravenous deguelin and Parkinson's disease in rats. The study does not suggest that deguelin exposure is responsible for Parkinson's disease in humans, but is consistent with the belief that chronic exposure to environmental toxins can increase the likelihood of the disease.